Fixed Combination Lisinopril Plus Hydrochlorothiazide in the Treatment of Essential Arterial Hypertension: An Opened, Multi-Centre, Prospective Clinical Trial

  • Vjekoslav Gerc Clinic for Heart Diseases and Rheumatism, Clinical Center University of Sarajevo
  • Begler Begović Institute for Clinical Pharmacology, University of Sarajevo Clinics Centre
  • Midhat Vehabović Bosnalijek dd
  • Leonid Georgievich Voronkov Institute of Cardiology of Academy of Medical Sciences of Ukraine
  • Eleonora Vataman Scientific Departments of Medicale
  • Ljiljana Musić Clinic for Heart Diseases, Clinical Center of Montenegro
  • Marko Bukša Clinic for Heart Diseases and Rheumatism, Clinical Center University of Sarajevo
  • Zumreta Kušljugić Department of Cardiology, University Clinical Center Tuzla
  • Maria Grigorevna Ilyash City hospital № 8
  • Larisa Michaylovna Ena City hospital № 1
  • Vera Iosifovna Tchelujko Regional Cardiological Clinic
  • Alexander Ivanovich Dyaduk City hospital № 8
  • Andrey Eduardovich Bagrij City hospital № 1
  • Svetlana Alekseevna Andrievskaja Regional cardiological clinic
  • Aleksandar Lazarević Clinic for Internal Diseases, Clinical Centre
  • Božidarka Knežević Clinic for Heart Diseases, Clinical Center of Montenegro
  • Faik Hima Internal Clinic UCC Pristina
Keywords: essential hypertension, lisinopril, hydrochlorthiazide

Abstract

The aim of this trial was to examine the efficacy and safety of antihypertensive fixed combination lisinopril plus hydrochlorothiazide (Lopril H, Bosnalijek dd) in the treatment of essential arterial hypertension.

In our trial we included 297 patients, aged 54,65±9,6 years, with treated or untreated hypertension and with high risk of cardiac events, in an opened trial of therapy based on lisinopril plus hydrochlorothiazide. Upon the examination by physicians, patients were divided into three groups in accordance with European Society of Cardiology guidelines for the management of arterial hypertension. Patients from five European countries were followed up for a period of 12 weeks. Duration of treatment was 12 weeks. We adjusted daily doses of lisinopril plus hydrochlorothiazide after every clinical examination and recorded adverse effects of drugs.

After 12 weeks of treatment, 288 patients (96%) were evaluated for efficacy, tolerability and safety. In almost 81,5% patients with mild, moderate and severe hypertension, we recorded a reduction in blood pressure to approximately normal values SBP and DBP (140/90 mmHg). Drug-related side-effects occurred in 11 patients (3,66%). The most commonly reported adverse effects associated with lisinopril plus hydrochlorothiazide were cough (5) and dry mouth (5).

This research has proved good efficacy of fixed combination lisinopril plus hydrochlorothiazide with more than 97% patients. Based on subjective estimation by patients: this drug improved quality of life in all cases.

Downloads

Download data is not yet available.
Fixed Combination Lisinopril Plus Hydrochlorothiazide in the Treatment of Essential Arterial Hypertension: An Opened, Multi-Centre, Prospective Clinical Trial
Published
2007-11-20
How to Cite
1.
Gerc V, Begović B, Vehabović M, Georgievich Voronkov L, Vataman E, Musić L, Bukša M, Kušljugić Z, Grigorevna Ilyash M, Michaylovna Ena L, Iosifovna Tchelujko V, Ivanovich Dyaduk A, Eduardovich Bagrij A, Alekseevna Andrievskaja S, Lazarević A, Knežević B, Hima F. Fixed Combination Lisinopril Plus Hydrochlorothiazide in the Treatment of Essential Arterial Hypertension: An Opened, Multi-Centre, Prospective Clinical Trial. Bosn J of Basic Med Sci [Internet]. 2007Nov.20 [cited 2020Jul.11];7(4):377-82. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/3031
Section
Translational and Clinical Research